Proglumide exhibits delta opioid agonist properties.

Area of Science:

• Neuropharmacology
• Opioid Receptor Research

Background:

• Proglumide, a cholecystokinin (CCK) antagonist, is known to potentiate opioid analgesia.
• Its precise mechanism, particularly regarding opioid receptor interactions, requires further elucidation.

Purpose of the Study:

• To investigate the effects of proglumide on opioid systems in peripheral tissues.
• To determine the in vitro binding affinity of proglumide to opioid receptors.

Main Methods:

• Electrically stimulated muscle preparations (guinea pig ileum, mouse, rat, rabbit vas deferens).
• In vitro binding assays using mouse brain synaptosomes and specific opioid receptor ligands.
• Assessment of proglumide's interaction with naloxone and delta-opioid antagonists.

Main Results:

• Proglumide dose-dependently inhibited contractions in the mouse vas deferens and guinea pig ileum.
• These inhibitory effects on the mouse vas deferens were antagonized by naloxone and a delta-opioid antagonist.
• Proglumide displaced a delta-opioid agonist (DADLE) in binding studies, indicating interaction with delta-opioid receptors.

Conclusions:

• Proglumide exhibits opiate-like effects, potentially through the activation of delta-opioid receptors.
• The findings suggest a presynaptic mechanism of action for proglumide's effects on opioid systems.